Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925178 | 1.00 | KDM4E (0.44) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL16914367 | 0.84 | KDM4E (0.45) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL20385872 | 0.84 | KDM4E (0.45) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL31184024 | 0.84 | KDM4E (0.45) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL5895563 | 0.82 | KDM4E (0.43) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL5895200 | 0.81 | GPR119 (0.43) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL5895894 | 0.81 | DDB1 (0.47) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL5895810 | 0.80 | ALDH1A1 (0.43) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL4792848 | 0.79 | DDB1 (0.43) | KDM4EMAPTTHRBHPGDDDB1 | |
| SCHEMBL24089120 | 0.79 | USP2 (0.50) | KDM4EMAPTTHRBHPGDDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220073537-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | KDM4E 937/4885MAPT 4821/4885THRB 751/4885 |
| US-20220073537-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | KDM4E 937/4885MAPT 4821/4885THRB 751/4885 |
| US-20220396585-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | KDM4E 937/4885MAPT 4821/4885THRB 751/4885 |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | KDM4E 937/4885MAPT 4821/4885THRB 751/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | KDM4E 943/4885MAPT 4106/4885THRB 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.